FI126979B - Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö - Google Patents

Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö Download PDF

Info

Publication number
FI126979B
FI126979B FI20165153A FI20165153A FI126979B FI 126979 B FI126979 B FI 126979B FI 20165153 A FI20165153 A FI 20165153A FI 20165153 A FI20165153 A FI 20165153A FI 126979 B FI126979 B FI 126979B
Authority
FI
Finland
Prior art keywords
formulation
beta
inf
tween
sucrose
Prior art date
Application number
FI20165153A
Other languages
English (en)
Swedish (sv)
Other versions
FI20165153A (fi
Inventor
Markku Jalkanen
Mikael Maksimow
Ilse Piippo
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Priority to FI20165153A priority Critical patent/FI126979B/fi
Priority to US15/355,691 priority patent/US10293030B2/en
Priority to PL17711246.3T priority patent/PL3423042T3/pl
Priority to BR112018016545-0A priority patent/BR112018016545B1/pt
Priority to HRP20220896TT priority patent/HRP20220896T1/hr
Priority to CA3011609A priority patent/CA3011609C/en
Priority to RS20220686A priority patent/RS63429B1/sr
Priority to ES17711246T priority patent/ES2922481T3/es
Priority to DK17711246.3T priority patent/DK3423042T3/da
Priority to CN202211127783.0A priority patent/CN115364060A/zh
Priority to PCT/FI2017/050128 priority patent/WO2017149199A1/en
Priority to KR1020187022141A priority patent/KR20180114018A/ko
Priority to SI201731182T priority patent/SI3423042T1/sl
Priority to HUE17711246A priority patent/HUE059550T2/hu
Priority to JP2018545331A priority patent/JP6869255B2/ja
Priority to AU2017225236A priority patent/AU2017225236B2/en
Priority to CN201780002738.3A priority patent/CN107921001A/zh
Priority to LTEPPCT/FI2017/050128T priority patent/LT3423042T/lt
Priority to PT177112463T priority patent/PT3423042T/pt
Priority to EP17711246.3A priority patent/EP3423042B1/en
Publication of FI20165153A publication Critical patent/FI20165153A/fi
Application granted granted Critical
Publication of FI126979B publication Critical patent/FI126979B/fi
Priority to HK18109617.4A priority patent/HK1250147A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (16)

1. Farmaseuttinen formulaatio lyofilisoidussa muodossa, joka formulaatio käsittää interferonibeeta-1a:ta aktiivisena ainesosana, jonka määrä on 2,0-15 pg, yksittäisannosmuodossa, disakkarideja täyteaineena ja ei-ioniaktiivista pinta-aktiivisuusainetta.
2. Patenttivaatimuksen 1 mukainen formulaatio, jossa mainittu formulaatio käsittää puskurointiainetta noin pH:n 5,5 - 7,5 ylläpitämiseksi lyofilisoidun formulaation uudelleen muodostamisen jälkeen, ja edullisesti antioksidantin.
3. Patenttivaatimuksen 1 tai 2 mukainen formulaatio, jossa mainitut disakka-ridit valitaan trehaloosidihydraatista ja sukroosista.
4. Jonkin edellisen patenttivaatimuksen mukainen formulaatio, jossa mainittu ei-ioniaktiivinen pinta-aktiivisuusaine on polysorbaatti tai polyeteeniglykoli (PEG).
5. Jonkin edellisen patenttivaatimuksen 2-4 mukainen formulaatio, jossa mainittu formulaatio käsittää dinatriumfosfaattidihydraattia, natriumdivetyfos-faattidihydraattia, trinatriumsitraattidihydraattia tai niiden yhdistelmää pusku-rointiaineena.
6. Jonkin edellisen patenttivaatimuksen 2-5 mukainen formulaatio, jossa mainittu antioksidantti on metioniini.
7. Jonkin edellisen patenttivaatimuksen mukainen formulaatio, jossa interfe-ronibeeta-1a on ihmisen rekombinantti interferonibeeta-1a.
8. Jonkin edellisen patenttivaatimuksen mukainen formulaatio, jossa mainitun lyofilisoidun formulaation jäännöskosteuspitoisuus on alle 5 painoprosenttia, edullisesti alueella 1-5 %.
9. Jonkin edellisen patenttivaatimuksen mukainen formulaatio, jossa formulaatio on valmistettu vesipitoisesta liuoksesta, jonka pH on 5,5-7,5 ja joka käsittää (i) ihmisen rekombinanttia beeta-1a:ta aktiivisena ainesosana, (ii) trehaloosidihydraattia tai sukroosia täyteaineena, (iii) polysorbaattia tai polyeteeniglykolia pinta-aktiivisuusaineena, (iv) dinatriumfosfaattidihydraatin, natriumdivetyfosfaattidihydraatin ja trinatriumsitraattidihydraatin yhdistelmän puskurointiaineena, ja (v) metioniinia antioksidanttina.
10. Patenttivaatimuksen 9 mukainen formulaatio, jossa vesipitoinen liuos käsittää 0,05-0,15 % (w/v) polysorbaattia tai polyeteeniglykolia, edullisesti polysorbaattia, ja 2-6 % (w/v) trehaloosidihydraattia tai sukroosia.
11. Vesipitoinen farmaseuttinen koostumus, joka on saatu muodostamalla uudelleen jonkin edellisen patenttivaatimuksen 1-10 mukainen lyofilisoitu formulaatio.
12. Patenttivaatimuksen 11 mukainen vesipitoinen farmaseuttinen koostumus suonensisäiseen annosteluun.
13. Annostelulaite sisältäen patenttivaatimuksen 11 mukaisen vesipitoisen farmaseuttisen koostumuksen.
14. Esitäytetty ruisku sisältäen patenttivaatimuksen 11 mukaisen vesipitoisen farmaseuttisen koostumuksen.
15. Patenttivaatimuksen 13 mukainen annostelulaite tai patenttivaatimuksen 14 mukainen esitäytetty ruisku, jolloin annostelulaitteen tai esitäytetyn ruiskun sisäpinta on silikonisoitu.
16. Jonkin patenttivaatimuksen 1-10 mukainen lyofilisoitu formulaatio tai patenttivaatimuksen 11 mukainen farmaseuttinen koostumus käytettäväksi sairauden tai häiriön ehkäisyyn ja/tai hoitoon, joka sairaus tai häiriö on valittu seuraavista -verisuonivuoto äkillisessä hengitysvaikeusoireyhtymässä (ARDS) tai systeeminen tulehdusvastesyndrooma (SIRS), -iskemiareperfuusiovaurio verisuoni- tai sydänkirurgiassa ja elinsiirrossa -iskeeminen esikäsittely ennen suurempaa verisuoni- tai sydänleikkausta ja elinsiirtoa, -monielinvaurio (MOF).
FI20165153A 2016-02-29 2016-02-29 Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö FI126979B (fi)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FI20165153A FI126979B (fi) 2016-02-29 2016-02-29 Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö
US15/355,691 US10293030B2 (en) 2016-02-29 2016-11-18 Lyophilised pharmaceutical formulation and its use
HUE17711246A HUE059550T2 (hu) 2016-02-29 2017-02-28 Liofilizált gyógyászati készítmény és alkalmazása
HRP20220896TT HRP20220896T1 (hr) 2016-02-29 2017-02-28 Liofilizirana farmaceutska formulacija i njena upotreba
CA3011609A CA3011609C (en) 2016-02-29 2017-02-28 A lyophilised pharmaceutical formulation and its use
RS20220686A RS63429B1 (sr) 2016-02-29 2017-02-28 Liofilizovana farmaceutska formulacija i njena upotreba
ES17711246T ES2922481T3 (es) 2016-02-29 2017-02-28 Formulación farmacéutica liofilizada y su uso
DK17711246.3T DK3423042T3 (da) 2016-02-29 2017-02-28 Lyofiliseret farmaceutisk formulering og anvendelse deraf
CN202211127783.0A CN115364060A (zh) 2016-02-29 2017-02-28 一种冻干药物制剂及其用途
PCT/FI2017/050128 WO2017149199A1 (en) 2016-02-29 2017-02-28 A lyophilised pharmaceutical formulation and its use
PL17711246.3T PL3423042T3 (pl) 2016-02-29 2017-02-28 Liofilizowany preparat farmaceutyczny i jego zastosowanie
SI201731182T SI3423042T1 (sl) 2016-02-29 2017-02-28 Liofilizirana farmacevtska formulacija in njena uporaba
BR112018016545-0A BR112018016545B1 (pt) 2016-02-29 2017-02-28 Formulação farmacêutica liofilizada e seu uso
JP2018545331A JP6869255B2 (ja) 2016-02-29 2017-02-28 凍結医薬製剤およびその使用
AU2017225236A AU2017225236B2 (en) 2016-02-29 2017-02-28 A lyophilised pharmaceutical formulation and its use
CN201780002738.3A CN107921001A (zh) 2016-02-29 2017-02-28 一种冻干药物制剂及其用途
LTEPPCT/FI2017/050128T LT3423042T (lt) 2016-02-29 2017-02-28 Liofilizuota farmacinė vaisto forma ir jos panaudojimas
PT177112463T PT3423042T (pt) 2016-02-29 2017-02-28 Formulação farmacêutica liofilizada e sua utilização
EP17711246.3A EP3423042B1 (en) 2016-02-29 2017-02-28 A lyophilised pharmaceutical formulation and its use
KR1020187022141A KR20180114018A (ko) 2016-02-29 2017-02-28 동결 건조된 약학적 제제 및 그의 용도
HK18109617.4A HK1250147A1 (zh) 2016-02-29 2018-07-25 一種凍干藥物製劑及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20165153A FI126979B (fi) 2016-02-29 2016-02-29 Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö

Publications (2)

Publication Number Publication Date
FI20165153A FI20165153A (fi) 2017-08-30
FI126979B true FI126979B (fi) 2017-09-15

Family

ID=58347412

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20165153A FI126979B (fi) 2016-02-29 2016-02-29 Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö

Country Status (20)

Country Link
US (1) US10293030B2 (fi)
EP (1) EP3423042B1 (fi)
JP (1) JP6869255B2 (fi)
KR (1) KR20180114018A (fi)
CN (2) CN115364060A (fi)
AU (1) AU2017225236B2 (fi)
BR (1) BR112018016545B1 (fi)
CA (1) CA3011609C (fi)
DK (1) DK3423042T3 (fi)
ES (1) ES2922481T3 (fi)
FI (1) FI126979B (fi)
HK (1) HK1250147A1 (fi)
HR (1) HRP20220896T1 (fi)
HU (1) HUE059550T2 (fi)
LT (1) LT3423042T (fi)
PL (1) PL3423042T3 (fi)
PT (1) PT3423042T (fi)
RS (1) RS63429B1 (fi)
SI (1) SI3423042T1 (fi)
WO (1) WO2017149199A1 (fi)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340587B2 (en) * 2009-06-25 2016-05-17 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150067A3 (en) 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5556771A (en) 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
JP4883665B2 (ja) 2002-07-17 2012-02-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターフェロン−βを使用する腎不全のための治療法
ATE471720T1 (de) 2003-03-28 2010-07-15 Faron Pharmaceuticals Oy Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
ES2414705T3 (es) * 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
BRPI0513332A (pt) * 2004-08-12 2008-05-06 Schering Corp formulação de interferon peguilado estável
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta

Also Published As

Publication number Publication date
PL3423042T3 (pl) 2022-09-19
EP3423042B1 (en) 2022-04-27
US20170246254A1 (en) 2017-08-31
SI3423042T1 (sl) 2022-10-28
CN107921001A (zh) 2018-04-17
EP3423042A1 (en) 2019-01-09
JP6869255B2 (ja) 2021-05-12
BR112018016545B1 (pt) 2023-10-10
JP2019513123A (ja) 2019-05-23
PT3423042T (pt) 2022-07-25
FI20165153A (fi) 2017-08-30
LT3423042T (lt) 2022-08-10
BR112018016545A2 (pt) 2018-12-26
WO2017149199A1 (en) 2017-09-08
KR20180114018A (ko) 2018-10-17
AU2017225236A1 (en) 2018-08-02
DK3423042T3 (da) 2022-07-18
CN115364060A (zh) 2022-11-22
US10293030B2 (en) 2019-05-21
CA3011609C (en) 2023-10-10
AU2017225236B2 (en) 2022-03-31
ES2922481T3 (es) 2022-09-15
CA3011609A1 (en) 2017-09-08
HRP20220896T1 (hr) 2022-10-14
HUE059550T2 (hu) 2022-11-28
RS63429B1 (sr) 2022-08-31
HK1250147A1 (zh) 2018-11-30

Similar Documents

Publication Publication Date Title
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
US7879805B2 (en) High temperature stable peptide formulation
ES2706296T3 (es) Formulaciones de Factor VIII
CN107249622B (zh) 包含纤溶酶原的药物组合物和其用途
IL258298A (en) Methods for the production of stable glucagon preparations in protozoan polar solvents
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
JP2024003211A (ja) 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤
JP2019504043A (ja) コラーゲン７組成物及びそれを用いる方法
JPWO2017164349A1 (ja) ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物
AU778208B2 (en) GRF-containing lyophilized pharmaceutical compositions
JP6445169B2 (ja) α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤
WO2022034545A1 (en) Etelcalcetide formulations for parenteral use
WO2024133908A1 (en) Stable pharmaceutical compositions comprising romiplostim
CN116685309A (zh) 改善的冻干制剂
AU2005200879B2 (en) GRF-containing lyophilized pharmaceutical compositions

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 126979

Country of ref document: FI

Kind code of ref document: B